SCHEMBL1255442

SCHEMBL1255442

CCCC[Sn](CCCC)(CCCC)c1ccccc1C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
HSD11B1 P28845 3/20 0.35
TLR8 Q9NR97 1/20 0.35
AR P10275 2/20 0.34
ALDH1A1 P00352 2/20 0.33
NOS3 P29474 2/20 0.33
NOS1 P29475 2/20 0.33
NOS2 P35228 2/20 0.33
IDO1 P14902 2/20 0.33
KDM4E B2RXH2 1/20 0.33
HPGD P15428 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ALPL P05186 1/20 0.33
ALPG P10696 1/20 0.33
EPHX2 P34913 1/20 0.33
POLQ O75417 1/20 0.33
POLB P06746 1/20 0.32
MAPK1 P28482 1/20 0.32
HSD11B2 P80365 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5952904 0.84 ALDH1A1 (0.36) ALDH1A1TDP1
SCHEMBL7505763 0.76 SMN1; SMN2 (0.36) TLR8ALDH1A1TDP1
SCHEMBL31558464 0.76 SMN1; SMN2 (0.36) TLR8ALDH1A1TDP1
SCHEMBL31319231 0.73 EPHX2 (0.34) HSD11B1TLR8AREPHX2
SCHEMBL21552099 0.73 LMNA (0.36) KDM4E
SCHEMBL1453183 0.73 TSHR (0.36) TLR8ALDH1A1
SCHEMBL3848205 0.72 RECQL (0.36) ALDH1A1
SCHEMBL11202895 0.72 TSHR (0.39) ALDH1A1KDM4EHPGDTDP1POLB
SCHEMBL3227093 0.72 CYP1A2 (0.44) TLR8ALDH1A1KDM4ETDP1POLB
SCHEMBL2650519 0.71 TSHR (0.42) TLR8ARALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3002283-B1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO LTD (JP) 2017-06-14 EP disclosed
EP-3002283-A1 THIAZOLE DERIVATIVES Kyowa Hakko Kirin Co., Ltd. (JP) 2016-04-06 EP disclosed
EP-1700856-B1 THIAZOLE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2015-11-11 EP disclosed
US-8889718-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-11-18 US disclosed
US-20130267509-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-10-10 US disclosed
US-8420827-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-04-16 US disclosed
US-20110105486-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-05-05 US disclosed
US-7880013-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-01 US disclosed
US-20100256361-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
US-7718808-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-05-18 US disclosed
US-7384960-B2 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2008-06-10 US disclosed
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-10 US disclosed
EP-1700856-A1 THIAZOLE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-13 EP disclosed
US-20050192332-A1 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2005-09-01 US disclosed
US-6906080-B1 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2005-06-14 US disclosed
EP-0805813-B1 TRICYCLIC VASOPRESSIN ANTAGONISTS AMERICAN CYANAMID CO (US) 2002-05-15 EP disclosed
US-5780471-A Tricyclic benzazepine vasopressin antagonists AMERICAN CYANAMID COMPANY (US) 1998-07-14 US disclosed
WO-1996022292-A1 TRICYCLIC VASOPRESSIN ANTAGONISTS AMERICAN CYANAMID COMPANY (US) 1996-07-25 WO disclosed
US-5521173-A TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER AMERICAN HOME PRODUCTS CORPORATION (US) 1996-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267509-A1 THIAZOLE DERIVATIVES THRA, CHD8, CYP2C8 SLC6A2 2591/4885SLC6A4 3214/4885HSD11B1 2617/4885
US-20110105486-A1 THIAZOLE DERIVATIVES CHD8, CYP2C8, THRA SLC6A2 4743/4885SLC6A4 4656/4885HSD11B1 2258/4885
US-20100256361-A1 THIAZOLE DERIVATIVES ADORA2A, ADORA3, ADORA1 SLC6A2 1194/4885SLC6A4 647/4885HSD11B1 2722/4885
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders ADORA2A, ADORA3, ADORA1 SLC6A2 428/4885SLC6A4 595/4885HSD11B1 4236/4885
US-20050192332-A1 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same CNR1, CNR2, CBR3 SLC6A2 3999/4885SLC6A4 2820/4885HSD11B1 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.